High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: Results of a Spanish multicentre observational study

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 983bf1040d4aeb34-LAX IP: 118.31.43.22 UTC time: 2025-09-23T18:00:25+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4